Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 23 Mar 2022 for Galecto, Inc., €29k. Read the official filing
Filing timeline
BuySaleBertil Lindmark
Insider track record
Disclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Bertil Lindmark: trading record in brief
Bertil Lindmark (senior executive) discloses dealings in Damora Therapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 28 June 2021 to 22 March 2022, the count stands at 2 filings.
On the market, this insider has only ever bought: 2 purchases, €37k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2022 to date brings 1 purchase and no sales.
On 23 March 2022 came the latest disclosure, an open-market purchase for €29k in Damora Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Bertil Lindmark
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
14,604 shares@ US$2.1676.5% of flowCommon StockSEC:0001209191-22-020683:0
Canonical exit: 20 Jun 2022 (T+90)
2,000 shares@ US$5.2623.5% of flowCommon StockSEC:0001209191-21-043464:0
Canonical exit: 26 Sept 2021 (T+90)
2 of 2 declarations
